Clinical Trial Update: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) [Phase 3]

View source ↗

Summary

Phase 3 trial FLAURA2 compares osimertinib with or without chemotherapy as first-line treatment for EGFR-mutated non-small cell lung cancer; results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-06